Cargando…
Drug screening using model systems: some basics
An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the im...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117237/ https://www.ncbi.nlm.nih.gov/pubmed/27821602 http://dx.doi.org/10.1242/dmm.028159 |
_version_ | 1782468780534792192 |
---|---|
author | Cagan, Ross |
author_facet | Cagan, Ross |
author_sort | Cagan, Ross |
collection | PubMed |
description | An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the importance of doing some homework before you start screening. 'Lead hits', 'patentable chemical space' and 'druggability' are all concepts worth exploring when deciding which screening path to take. I discuss some of the lessons I learned that may be useful as you navigate the screening matrix. |
format | Online Article Text |
id | pubmed-5117237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51172372016-12-12 Drug screening using model systems: some basics Cagan, Ross Dis Model Mech Editorial An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the importance of doing some homework before you start screening. 'Lead hits', 'patentable chemical space' and 'druggability' are all concepts worth exploring when deciding which screening path to take. I discuss some of the lessons I learned that may be useful as you navigate the screening matrix. The Company of Biologists Ltd 2016-11-01 /pmc/articles/PMC5117237/ /pubmed/27821602 http://dx.doi.org/10.1242/dmm.028159 Text en © 2016. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Editorial Cagan, Ross Drug screening using model systems: some basics |
title | Drug screening using model systems: some basics |
title_full | Drug screening using model systems: some basics |
title_fullStr | Drug screening using model systems: some basics |
title_full_unstemmed | Drug screening using model systems: some basics |
title_short | Drug screening using model systems: some basics |
title_sort | drug screening using model systems: some basics |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117237/ https://www.ncbi.nlm.nih.gov/pubmed/27821602 http://dx.doi.org/10.1242/dmm.028159 |
work_keys_str_mv | AT caganross drugscreeningusingmodelsystemssomebasics |